J
Jean-Paul Achkar
Researcher at Cleveland Clinic
Publications - 77
Citations - 11478
Jean-Paul Achkar is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Crohn's disease & Inflammatory bowel disease. The author has an hindex of 20, co-authored 60 publications receiving 10393 citations. Previous affiliations of Jean-Paul Achkar include Cleveland Clinic Lerner Research Institute.
Papers
More filters
Journal ArticleDOI
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Yasunori Ogura,Denise K. Bonen,Naohiro Inohara,Dan L. Nicolae,Felicia F. Chen,Richard Ramos,Heidi M. Britton,Thomas M. Moran,Reda Karaliuskas,Richard H. Duerr,Jean-Paul Achkar,Steven R. Brant,Theodore M. Bayless,Barbara S. Kirschner,Stephen B. Hanauer,Gabriel Núñez,Judy H. Cho +16 more
TL;DR: It is shown that a frameshift mutation caused by a cytosine insertion, 3020insC, which is expected to encode a truncated NOD2 protein, is associated with Crohn's disease, and a link between an innate immune response to bacterial components and development of disease is suggested.
Journal ArticleDOI
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease
Luke Jostins,Stephan Ripke,Rinse K. Weersma,Richard H. Duerr,Dermot P.B. McGovern,Ken Y. Hui,James Lee,L. Philip Schumm,Yashoda Sharma,Carl A. Anderson,Jonah Essers,Mitja Mitrovic,Kaida Ning,Isabelle Cleynen,Emilie Theatre,Sarah L. Spain,Soumya Raychaudhuri,Philippe Goyette,Zhi Wei,Clara Abraham,Jean-Paul Achkar,Tariq Ahmad,Leila Amininejad,Ashwin N. Ananthakrishnan,Vibeke Andersen,Jane M. Andrews,Leonard Baidoo,Tobias Balschun,Peter A. Bampton,Alain Bitton,Gabrielle Boucher,Stephan Brand,Carsten Büning,Ariella Cohain,Sven Cichon,Mauro D'Amato,Dirk De Jong,Kathy L Devaney,Marla Dubinsky,Cathryn Edwards,David Ellinghaus,Lynnette R. Ferguson,Denis Franchimont,Karin Fransen,Richard B. Gearry,Michel Georges,Christian Gieger,Jürgen Glas,Talin Haritunians,Ailsa Hart,Christopher J. Hawkey,Matija Hedl,Xinli Hu,Tom H. Karlsen,Limas Kupčinskas,Subra Kugathasan,Anna Latiano,Debby Laukens,Ian C. Lawrance,Charlie W. Lees,Edouard Louis,Gillian Mahy,John C. Mansfield,Angharad R. Morgan,Craig Mowat,William G. Newman,Orazio Palmieri,Cyriel Y. Ponsioen,Uroš Potočnik,Natalie J. Prescott,Miguel Regueiro,Jerome I. Rotter,Richard K Russell,Jeremy D. Sanderson,Miquel Sans,Jack Satsangi,Stefan Schreiber,Lisa A. Simms,Jurgita Sventoraityte,Stephan R. Targan,Kent D. Taylor,Mark Tremelling,Hein W. Verspaget,Martine De Vos,Cisca Wijmenga,David C. Wilson,Juliane Winkelmann,Ramnik J. Xavier,Sebastian Zeissig,Bin Zhang,Clarence K. Zhang,Hongyu Zhao,Mark S. Silverberg,Vito Annese,Hakon Hakonarson,Steven R. Brant,Graham L. Radford-Smith,Christopher G. Mathew,John D. Rioux,Eric E. Schadt,Mark J. Daly,Andre Franke,Miles Parkes,Severine Vermeire,Jeffrey C. Barrett,Judy H. Cho +105 more
TL;DR: A meta-analysis of Crohn’s disease and ulcerative colitis genome-wide association scans is undertaken, followed by extensive validation of significant findings, with a combined total of more than 75,000 cases and controls.
Journal ArticleDOI
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis
Jimmy Z. Liu,Johannes R. Hov,Trine Folseraas,Trine Folseraas,Eva Ellinghaus,Simon M. Rushbrook,Nadezhda Tsankova Doncheva,Ole A. Andreassen,Ole A. Andreassen,Rinse K. Weersma,Tobias J. Weismüller,Bertus Eksteen,Pietro Invernizzi,Gideon M. Hirschfield,Gideon M. Hirschfield,Daniel Gotthardt,Albert Parés,David Ellinghaus,Tejas Shah,Brian D. Juran,Piotr Milkiewicz,Christian Rust,Christoph Schramm,Tobias Müller,Brijesh Srivastava,Georgios N. Dalekos,Markus M. Nöthen,Stefan Herms,Juliane Winkelmann,Mitja Mitrovic,Felix Braun,Cyriel Y. Ponsioen,Peter J. P. Croucher,Martina Sterneck,Andreas Teufel,Andrew Mason,Janna Saarela,Virpi Leppa,Ruslan Dorfman,Domenico Alvaro,Annarosa Floreani,Suna Onengut-Gumuscu,Stephen S. Rich,Wesley K. Thompson,Andrew J. Schork,Sigrid Næss,Sigrid Næss,Ingo Thomsen,Gabriele Mayr,Inke R. König,Kristian Hveem,Isabelle Cleynen,Isabelle Cleynen,Javier Gutierrez-Achury,Isis Ricaño-Ponce,David A. van Heel,Einar Björnsson,Richard Sandford,Peter R. Durie,Espen Melum,Espen Melum,Morten H. Vatn,Morten H. Vatn,Morten H. Vatn,Mark S. Silverberg,Richard H. Duerr,Leonid Padyukov,Stephan Brand,Miquel Sans,Vito Annese,Jean-Paul Achkar,Jean-Paul Achkar,Kirsten Muri Boberg,Kirsten Muri Boberg,Hanns-Ulrich Marschall,Olivier Chazouillères,Christopher L. Bowlus,Cisca Wijmenga,Erik Schrumpf,Erik Schrumpf,Severine Vermeire,Mario Albrecht,John D. Rioux,John D. Rioux,Graeme J.M. Alexander,Annika Bergquist,Judy H. Cho,Stefan Schreiber,Michael P. Manns,Martti Färkkilä,Anders M. Dale,Roger W. Chapman,Konstantinos N. Lazaridis,Andre Franke,Carl A. Anderson,Tom H. Karlsen +95 more
TL;DR: This analysis compared 3,789 PSC cases of European ancestry to 25,079 population controls across 130,422 SNPs genotyped using the Immunochip to identify 12 genome-wide significant associations outside the human leukocyte antigen (HLA) complex, 9 of which were new, increasing the number of known PSC risk loci to 16.
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis
Jimmy Z. Liu,Johannes R. Hov,Trine Folseraas,Eva Ellinghaus,Simon M. Rushbrook,Nadezhda Tsankova Doncheva,Ole A. Andreassen,Rinse K. Weersma,Tobias J. Weismueller,Bertus Eksteen,Pietro Invernizzi,Gideon M. Hirschfield,Daniel Gotthardt,Albert Parés,David Ellinghaus,Tejas Shah,Brian D. Juran,Piotr Milkiewicz,Christian Rust,Christoph Schramm,Tobias Mueller,Brijesh Srivastava,Georgios N. Dalekos,Markus M. Noethen,Stefan Herms,Juliane Winkelmann,Mitja Mitrovic,Felix Braun,Cyriel Y. Ponsioen,Peter J. P. Croucher,Martina Sterneck,Andreas Teufel,Andrew Mason,Janna Saarela,Virpi Leppa,Ruslan Dorfman,Domenico Alvaro,Annarosa Floreani,Suna Onengut-Gumuscu,Stephen S. Rich,Wesley K. Thompson,Andrew J. Schork,Sigrid Næss,Ingo Thomsen,Gabriele Mayr,Inke R. Koenig,Kristian Hveem,Isabelle Cleynen,Javier Gutierrez-Achury,Isis Ricaño-Ponce,David A. van Heel,Einar Bjoernsson,Richard Sandford,Peter R. Durie,Espen Melum,Morten H. Vatn,Mark S. Silverberg,Richard H. Duerr,Leonid Padyukov,Stephan Brand,Miquel Sans,Vito Annese,Jean-Paul Achkar,Kirsten Muri Boberg,Hanns-Ulrich Marschall,Olivier Chazouillères,Christopher L. Bowlus,Cisca Wijmenga,Erik Schrumpf,Severine Vermeire,Mario Albrecht,John D. Rioux,Graeme J.M. Alexander,Annika Bergquist,Judy H. Cho,Stefan Schreiber,Michael P. Manns,Martti Färkkilä,Anders M. Dale,Roger W. Chapman,Konstantinos N. Lazaridis,Andre Franke,Carl A. Anderson,Tom H. Karlsen +83 more
Abstract: Primary sclerosing cholangitis (PSC) is a severe liver disease of unknown etiology leading to fibrotic destruction of the bile ducts and ultimately to the need for liver transplantation. We compared 3,789 PSC cases of European ancestry to 25,079 population controls across 130,422 SNPs genotyped using the Immunochip. We identified 12 genome-wide significant associations outside the human leukocyte antigen (HLA) complex, 9 of which were new, increasing the number of known PSC risk loci to 16. Despite comorbidity with inflammatory bowel disease (IBD) in 72% of the cases, 6 of the 12 loci showed significantly stronger association with PSC than with IBD, suggesting overlapping yet distinct genetic architectures for these two diseases. We incorporated association statistics from 7 diseases clinically occurring with PSC in the analysis and found suggestive evidence for 33 additional pleiotropic PSC risk loci. Together with network analyses, these findings add to the genetic risk map of PSC and expand on the relationship between PSC and other immune-mediated diseases.
Journal ArticleDOI
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection
Miguel Regueiro,Brian G. Feagan,Bin Zou,Jewel Johanns,Marion Blank,Marc Chevrier,S Plevy,John W. Popp,Freddy Cornillie,Milan Lukas,Silvio Danese,Paolo Gionchetti,Stephen B. Hanauer,Walter Reinisch,Walter Reinisch,William J. Sandborn,Dario Sorrentino,Dario Sorrentino,Paul Rutgeerts,H. Debinski,Timothy H. Florin,D. J. Hetzel,I. Lawrance,G. Radford-Smith,A. Sloss,D. Sorrentino,S. Gassner,T. Haas,G. Reicht,W. Reinisch,W. Reinisch,M. Strasser,Harald Vogelsang,Peter Bossuyt,O. Dewit,G. D'Haens,Denis Franchimont,Edouard Louis,Severine Vermeire,Charles N. Bernstein,Raymond Bourdages,N. Chiba,S. S. Dhalla,Brian G. Feagan,Richard N. Fedorak,J. R. Lachance,Remo Panaccione,M. Ropeleski,B. Singh Salh,Martin Lukas,J.-F. Colombel,Matthieu Allez,Pierre Desreumaux,J.L. Dupas,Jean-Charles Grimaud,Xavier Hébuterne,D. Laharie,Eric Lerebours,Laurent Peyrin-Biroulet,Jean-Marie Reimund,Stephanie Viennot,Frank Zerbib,C. Antoni,Raja Atreya,Daniel C. Baumgart,C. Berg,U. Boecker,G. Bramkamp,C. Bünning,Robert Ehehalt,Stefanie Howaldt,Torsten Kucharzik,H. G. Lamprecht,J. Mudter,J. C. Preiss,S. Schreiber,Ursula Seidler,István Altorjay,János Banai,Peter L. Lakatos,Márta Varga,Áron Vincze,Irit Avni-Biron,S. Fishman,Gerald Fraser,Eran Goldin,Daniel Rachmilewitz,V. F. Annese,Sandro Ardizzone,Livia Biancone,Fabrizio Bossa,Silvio Danese,Walter Fries,P. Gionchetti,Giovanni Maconi,Giovanni Terrosu,Paolo Usai,G R D’Haens,Richard B. Gearry,J. Hill,David Rowbotham,Michael Schultz,R. S. Stubbs,D. Wallace,Russell S. Walmsley,John Wyeth,Ewa Małecka-Panas,L. Paradowski,Jaroslaw Regula,I. P. Beales,Simon Campbell,A. B. Hawthorne,M Parkes,Simon Travis,Jean-Paul Achkar,B. W. Behm,Stephen J. Bickston,K. J. Brown,Michael Chiorean,W. J S Devilliers,D. E. Elliott,D. Grunkmeier,J. W. Hamilton,S. B. Hanauer,J. S. Hanson,R. Hardi,D. J. Helper,Hans H Herfarth,Peter D.R. Higgins,W. H. Holderman,R. Kottoor,M. D. Kreines,B. I. Leman,X. Li,Edward V. Loftus,M. Noar,I. Oikonomou,Jane E. Onken,K. A. Peterson,R. P. Phillips,Charles Randall,M. Ricci,T. Ritter,David T. Rubin,Michael Safdi,W J Sandborn,L. Sauberman,Ellen Scherl,R. P. Schwarz,S. Sedghi,Ira Shafran,Charles A. Sninsky,I. Stein,Jason M. Swoger,J. Vecchio,D. I. Weinberg,L. D. Wruble,V. Yajnik,Ziad Younes +158 more
TL;DR: Infliximab is not superior to placebo in preventing clinical recurrence after CD-related resection, however, infliximab does reduce endoscopic recurrence.